Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-11-27 Sale | 2024-12-02 5:18 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 5,250 | $24.89 | $130,688 | 168,556 (Direct) | View |
| 2024-10-28 Sale | 2024-10-30 6:04 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 6,250 | $28.56 | $178,485 | 173,806 (Direct) | View |
| 2024-10-18 Sale | 2024-10-22 4:23 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 716 | $30 | $21,483 | 343,311 (Indirect) | View |
| 2024-10-18 Sale | 2024-10-22 4:22 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 847 | $30 | $25,413 | 1,015,188 (Indirect) | View |
| 2024-10-18 Sale | 2024-10-22 4:21 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 924 | $30 | $27,723 | 1,002,892 (Indirect) | View |
| 2024-10-18 Sale | 2024-10-22 4:19 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 814 | $30 | $24,422 | 180,056 (Direct) | View |
| 2024-10-18 Sale | 2024-10-22 4:18 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,570 | $30 | $47,104 | 188,245 (Indirect Direct) | View |
| 2024-10-18 Sale | 2024-10-22 4:17 pm | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 816 | $30 | $24,482 | 266,268 (Direct) | View |
| 2024-10-15 Sale | 2024-10-17 5:06 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,270 | $27.67 | $35,143 | 189,815 (Indirect Direct) | View |
| 2024-10-08 Sale | 2024-10-10 8:39 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 51,145 | $28.11 | $1,437,585 | 1,016,035 (Indirect) | View |
| 2024-10-08 Sale | 2024-10-10 8:38 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 29,977 | $28.07 | $841,334 | 1,003,816 (Indirect) | View |
| 2024-10-08 Sale | 2024-10-10 8:36 pm | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 10,420 | $28.17 | $293,557 | 104,091 (Direct) | View |
| 2024-10-04 Sale | 2024-10-08 6:58 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 10,229 | $27.54 | $281,664 | 1,067,180 (Indirect) | View |
| 2024-10-04 Sale | 2024-10-08 6:57 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 14,936 | $27.51 | $410,867 | 1,033,793 (Indirect) | View |
| 2024-10-04 Sale | 2024-10-08 6:56 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 11,488 | $27.51 | $316,014 | 363,010 (Direct) | View |
| 2024-10-04 Sale | 2024-10-08 6:54 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 2,825 | $27.51 | $77,704 | 191,085 (Indirect Direct) | View |
| 2024-10-01 Sale | 2024-10-03 6:47 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 527 | $27.54 | $14,512 | 1,077,409 (Indirect) | View |
| 2024-10-01 Sale | 2024-10-03 6:45 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 526 | $27.54 | $14,485 | 1,048,729 (Indirect) | View |
| 2024-10-01 Sale | 2024-10-03 6:44 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 521 | $27.54 | $14,347 | 192,358 (Direct) | View |
| 2024-10-01 Sale | 2024-10-03 6:43 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 518 | $27.54 | $14,264 | 193,910 (Indirect Direct) | View |
| 2024-09-27 Sale | 2024-10-01 7:53 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 6,250 | $24.61 | $153,829 | 387,758 (Direct) | View |
| 2024-09-16 Sale | 2024-09-18 4:17 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,270 | $22.41 | $28,458 | 194,428 (Indirect Direct) | View |
| 2024-08-29 Sale | 2024-09-03 5:43 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $22.49 | $269,841 | 1,077,936 (Indirect) | View |
| 2024-08-27 Sale | 2024-08-29 6:36 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $22.54 | $95,782 | 199,129 (Direct) | View |
| 2024-08-26 Sale | 2024-08-28 7:48 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $22.89 | $274,718 | 1,049,255 (Indirect) | View |
| 2024-08-15 Sale | 2024-08-19 7:49 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,270 | $23.25 | $29,526 | 195,698 (Indirect Direct) | View |
| 2024-07-31 Sale | 2024-08-02 7:26 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 3,099 | $27.56 | $85,399 | 1,089,936 (Indirect) | View |
| 2024-07-31 Sale | 2024-08-02 7:25 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 2,270 | $27.56 | $62,555 | 1,061,255 (Indirect) | View |
| 2024-07-31 Sale | 2024-08-02 7:23 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 991 | $27.53 | $27,281 | 203,379 (Direct) | View |
| 2024-07-31 Sale | 2024-08-02 7:22 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 2,351 | $27.5 | $64,663 | 196,968 (Indirect Direct) | View |
| 2024-07-29 Sale | 2024-07-31 7:33 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $26.7 | $320,378 | 1,093,035 (Indirect) | View |
| 2024-07-29 Sale | 2024-07-31 7:31 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 5,250 | $26.68 | $140,052 | 204,370 (Direct) | View |
| 2024-07-25 Sale | 2024-07-29 5:39 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $24.92 | $299,073 | 1,240,587 (Indirect) | View |
| 2024-07-15 Sale | 2024-07-17 7:25 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,270 | $24.8 | $31,497 | 199,319 (Indirect Direct) | View |
| 2024-07-12 Sale | 2024-07-16 5:37 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 50,000 | $25.06 | $1,252,826 | 344,027 (Indirect) | View |
| 2024-07-12 Sale | 2024-07-16 5:34 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,000 | $25.07 | $75,195 | 209,620 (Direct) | View |
| 2024-07-01 Sale | 2024-07-03 4:31 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $22.89 | $274,736 | 1,105,035 (Indirect) | View |
| 2024-06-27 Sale | 2024-07-01 8:03 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $22.57 | $95,922 | 212,620 (Direct) | View |
| 2024-06-25 Sale | 2024-06-27 4:35 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $21.66 | $259,902 | 1,252,587 (Indirect) | View |
| 2024-06-17 Sale | 2024-06-20 7:20 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,270 | $21.48 | $27,278 | 200,589 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-11-27 Exercise | 2024-12-02 5:18 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 5,250 | $2.48 | 168,556 (Direct) | View |
| 2024-11-27 Exercise | 2024-12-02 5:18 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 5,250 | $0 | 168,556 (Direct) | View |
| 2024-10-28 Exercise | 2024-10-30 6:04 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 6,250 | $2.48 | 173,806 (Direct) | View |
| 2024-10-28 Exercise | 2024-10-30 6:04 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 6,250 | $0 | 173,806 (Direct) | View |
| 2024-10-18 Exercise | 2024-10-22 4:19 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 814 | $2.48 | 180,056 (Direct) | View |
| 2024-10-18 Exercise | 2024-10-22 4:19 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 814 | $0 | 180,056 (Direct) | View |
| 2024-10-18 Exercise | 2024-10-22 4:17 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 816 | $2.48 | 266,268 (Direct) | View |
| 2024-10-18 Exercise | 2024-10-22 4:17 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 816 | $0 | 266,268 (Direct) | View |
| 2024-10-08 Exercise | 2024-10-10 8:36 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 6,314 | $19.68 | 104,091 (Direct) | View |
| 2024-10-08 Exercise | 2024-10-10 8:36 pm | N/A 2029-05-16 | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 10,420 | $0 | 104,091 (Direct) | View |
| 2024-10-08 Exercise | 2024-10-10 8:36 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 4,106 | $5.52 | 104,091 (Direct) | View |
| 2024-10-04 Exercise | 2024-10-08 6:56 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 11,488 | $2.48 | 363,010 (Direct) | View |
| 2024-10-04 Exercise | 2024-10-08 6:56 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 11,488 | $0 | 363,010 (Direct) | View |
| 2024-10-01 Exercise | 2024-10-03 6:44 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 521 | $2.48 | 192,358 (Direct) | View |
| 2024-10-01 Exercise | 2024-10-03 6:44 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 521 | $0 | 192,358 (Direct) | View |
| 2024-09-27 Exercise | 2024-10-01 7:53 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 6,250 | $2.48 | 387,758 (Direct) | View |
| 2024-09-27 Exercise | 2024-10-01 7:53 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 6,250 | $0 | 387,758 (Direct) | View |
| 2024-08-27 Exercise | 2024-08-29 6:36 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $2.48 | 199,129 (Direct) | View |
| 2024-08-27 Exercise | 2024-08-29 6:36 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $0 | 199,129 (Direct) | View |
| 2024-07-31 Exercise | 2024-08-02 7:23 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 991 | $2.48 | 203,379 (Direct) | View |
| 2024-07-31 Exercise | 2024-08-02 7:23 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 991 | $0 | 203,379 (Direct) | View |
| 2024-07-29 Exercise | 2024-07-31 7:31 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 5,250 | $2.48 | 204,370 (Direct) | View |
| 2024-07-29 Exercise | 2024-07-31 7:31 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 5,250 | $0 | 204,370 (Direct) | View |
| 2024-07-12 Exercise | 2024-07-16 5:34 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,000 | $2.48 | 209,620 (Direct) | View |
| 2024-07-12 Exercise | 2024-07-16 5:34 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,000 | $0 | 209,620 (Direct) | View |
| 2024-06-27 Exercise | 2024-07-01 8:03 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $2.48 | 212,620 (Direct) | View |
| 2024-06-27 Exercise | 2024-07-01 8:03 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $0 | 212,620 (Direct) | View |